While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...

(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

Cassava shares are down 34c, or 12%, to $2.46 in pre-market trading after resuming following a halt for news pending.Light Up your Portfolio ...

Cassava Sciences faces a significant setback after announcing its drug Simufilam failed to achieve meaningful results in the ...

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show benefit in a second Phase III trial. The company is ...